Characteristics of immunity induced by viral antigen or conferred by antibody via different administration routes

Clinical and Experimental Immunology

Volumn 130, Issue 3, 2002, Pages 386-392

  Matsuoka, T ^a   Okamoto, Yoshitaka ^a   Matsuzaki, Z ^a   Endo, S ^a   Ito, E ^b   Tsutsumi, H ^c   Williamson, R A ^d   Sakurai, H ^d   Burton, D R ^d   Saito, I ^e  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SAPPORO MEDICAL UNIVERSITY   (Japan)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Administration rote; Antiviral antibody; F glycoprotein; Recombinant vaccinia virus; RSV

Indexed keywords

GLYCOPROTEIN; GLYCOPROTEIN F; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VACCINE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; IMMUNIZATION; LUNG; MALE; MONONUCLEAR CELL; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; NOSE; PATHOLOGY; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VACCINIA VIRUS; VIRUS IMMUNITY; VIRUS INFECTION; VIRUS REPLICATION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INJECTIONS, INTRAPERITONEAL; LUNG; MALE; MICE; MICE, INBRED C57BL; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; VIRAL FUSION PROTEINS; VIRUS REPLICATION;

EID: 18744391637     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2002.02003.x     Document Type: Article

References (32)

1. Kim HW, Arrobio JO, Brandt CD et al. Epidemiology of respiratory syncytial virus infection in Washington, D.C. 1. Importance of the virus in different respiratory tract disease syndromes and temporal distribution of infection. Am J Epidemiol 1973; 89:422-34.
2. Belsh RB, Van Voris LP, Mufson MA. Parenteral administration of live respiratory syncytial virus vaccine: Results of a field trial. J Infect Dis 1982; 145:311-9.
3. Norryby E, Akerlind B, Mufson MA. The immunobiology of respiratory syncytial virus vaccine: Prospects for a vaccine. Adv Exp Med Biol 1990; 257:147-53.
4. Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH. Field evalution of a respiratory syncytial virus vaccine and a trivarent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol 1969; 89:449-63.
5. McIntosh K, Masters HB, Orr I, Chao RK, Barkin RM. The immunologic response to infection with respiratory syncytial virus in infants. J Infect Dis 1978; 138:24-32.
6. McIntosh K, Fishaut JM. Immunopathologic mechanism in lower respiratory tract disease of infants due to respiratory syncytial virus. Prog Med Virol 1980; 26:94-118.
7. Prince GA, Jenson AB, Hemming VG et al. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactivated virus. J Virol 1986; 57:721-8.
8. Piedra PA. Respiratory syncytial virus vaccines: Recent developments. Pediatr Infect Dis J 2000; 19:805-8.
9. Openshaw PJ, Clarke SL, Record FM. Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. Int Immunol 1992; 4:493-500.
10. Pecbles RJ, Sheller JR Jr Collins RD, Jarzecka K, Mitchell DB, Graham BS. Respiratory syncytial virus (RSV)-induced airway hyper-responsiveness in allergically sensitized mice is inhibited by live RSV and exacerbated by formalin-inactivated RSV. J Infect Dis 2000; 182:671-7.
11. Boelen A, Andeweg A, Kwakkel J et al. Both immunization with a formalin-inactivated respiratory syncytial virus (RSV) vaccine and a mock antigen vaccine induce severe lung pathology and a Th2 cytokine profile in RSV-challenged mice. Vaccine 2000; 19:982-91.
12. Van Schaik SM, Welliver RC, Kimpen JK. Novel pathways in the pathognesis of respiratory syncytial virus disease. Padiatr Pulmonol 2000; 30:131-8.
13. Siber GR, Leszczynski J, Pena-Cruz V et al. Protective activity of a human respiratory syncytial virus immune globulin prepared from donors screened by microneutralization assay. J Infect Dis 1992; 165:456-63.
14. Sanchez PJ. Immunoprophylaxis of respiratory syncytial virus disease. Pediatr Infect Dis J 2000; 19:791-801.
15. Murphy BR, Collins PL, Lawrence L, Zubak J, Chanock RM, Prince GA. Immunosuppression of syncytial virus (RSV) pre-existing serum antibodies: Partial prevention by topical infection of the respiratory tract with vaccina virus-RSV recombinants. J General Virol 1989; 70:2185-90.
16. Ueba O. Respiratory syncytial virus. 1. Concentration and purification of the infectious virus. Acta Med Okayama 1978; 32:265-72.
17. Olmsted RA, Elango N, Prince GA et al. Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccina virus: Comparison of the individual contributions of the F and G glycoproteins to host immunity. Proc Natl Acad Sci USA 1986; 83:7462-6.
18. Barbas CF, Crowe JEJ Jr, Cabana D et al. Human monoclonal Fab fragments derived from a combinational library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity. Proc Natl Acad Sci USA 1992; 89:10164-8.
19. Tsutsumi H, Flanagan T, Ogra PL. Munoclonal antibodies to the large glycoproteins of respiratory syncytial virus: Posible evidence for several functional antigenic sites. J Gen Virol 1987; 68:2161-9.
20. Coates HV, Alling DW, Chanock RM. An antigenic analysis of respiratory syncytial virus isolates by plaque reduction neutralization test. Am J Epidemiol 1965; 83:299-313.
21. Liew FY, Russell SM, Appleyard G, Brand CM, Beale J. Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotocxic T cell reactivity. Eur J Immunol 1984; 14:350-6.
22. Mills J, Vankirk JE, Wright PF, Chanock RM. Experimental respiratory syncytial virus infection of adults. J Immunol 1971; 107:123-30.
23. McDermott MR, Bienenstock J. Evidence for a common mucosal immunologic system. 1. Migration of B immunoblasts into intestinal, respiratory, and genital tissues. J Immunol 1979; 122:1892-8.
24. Carrington PW, Roux ME, McWilliams M, Phillips-Quagliata JM, Lamm ME. Organ and isotype distribution of plasma cells producting specific antibody after oral immunization: Evidence for a generalized secretory immune system. J Immunol 1979; 123:1705-8.
25. Russell MW, Mestecky J. Induction of the mucosal immune response. Rev Infect Dis 1988; 10:s440-s446.
26. Kanesaki T, Murphy BR, Collins PL, Ogra PL. Effectiveness of enteric immunization in the development of secretory immunoglobulin A response and the outcome of infection with respiratory syncytial virus. J Virol 1991; 65:657-63.
27. McIntosh K, McQuillin J, Gardner PS. Cell-free and cell-bound antibody in nasal seretions from infants with respiratory syncytial virus infection. Infect Immune 1979; 23:276-81.
28. Kumagai T, Wong DT, Ogra PL. Development of cell-mediated cytotoxic activity in the respiratory tract after experimental infection with respiratory syncytial virus. Clin Exp Immunol 1985; 61:351-9.
29. Cannon MJ, Openshaw PJ, Askonas BA. Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus. J Exp Med 1988; 168:1163-8.
30. Murphy BR, Sotnikov AV, Lawrence LA, Banks SM, Prince GA. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine 1990; 8:497-502.
31. Graham BS Henderson GS, Tang Y, Lu X, Neuzil KM, Colley DG. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J Immunol 1993; 151:2032-40.
32. Vujovic O, Mills J. Preventive and therapeatic strategies for respiratory syncytial virus infection. Curr Op Pharmcol 2001; 1:497-503.